Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B) Peptide

Details for Product No. ABIN500862
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Protein Name
Synonyms CD267, CVID, CVID2, RYZN, TACI, TNFRSF14B, 1200009E08Rik, Taci, TNFRSF13B
Origin
Human
(6)
Application
Control Peptide (CP)
Pubmed 2 references available
Catalog no. ABIN500862
Quantity 50 µg
Price
170.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Specificity Control peptide for AP30855PU-N. Peptide consists of 15 amino amino terminus of human TACI.
Alternative Name CD267 / TACI
Background Alternate names: TNFRSF13B, Transmembrane activator and CAML interactor, Tumor necrosis factor receptor superfamily member 13B
Gene ID 23495
NCBI Accession NP_036584.1
Application Notes TACI peptide is used for blocking the antibody activity of TACI. It usually blocks theantibody activity completely in Western blot by incubating the peptide with equal volumeof antibody for 30 min at 37°C. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.2 mg/mL
Buffer PBS pH7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store (in aliquots) at -20°C.
Expiry Date 12 months
Background publications Geijtenbeek, Kwon, Torensma et al.: "DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells." in: Cell, Vol. 100, Issue 5, pp. 587-97, 2000 (PubMed).

Pöhlmann, Baribaud, Lee et al.: "DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus." in: Journal of virology, Vol. 75, Issue 10, pp. 4664-72, 2001 (PubMed).

Reactivities (6)
back to top